

“Seeing” Between the Lines

Irl B. Hirsch, MD

Diabetic retinopathy is the leading cause of blindness in the United States.¹ Approximately 5% of people with diabetes progress to severe visual loss of 5/200 or less. It is now clear that aggressive and early treatment of hyperglycemia per se in addition to appropriate screening with dilated eye exams can prevent much of the morbidity associated with this devastating complication.

In this issue, we are reprinting the American Diabetes Association’s position statement on diabetic retinopathy (p. 29). This statement reviews the natural history of diabetic retinopathy, its screening guidelines, and the efficacy of laser therapy as treatment for this complication. In addition, the statement covers several additional issues that primary care physicians may find useful in their daily practice.

The first is blood pressure control. It is clear that blood pressure control slows the progression of diabetic retinopathy.² There are now provocative data to suggest that angiotensin-converting enzyme (ACE) inhibitors may independently protect against the development or slow the progression of retinopathy,^{3,4} perhaps through reductions in retinal vascular endothelial growth factor levels.⁵

It also needs to be appreciated that rapid improvement of glycemic control may cause a *worsening* of preexisting retinopathy in both type 1 and type 2 diabetes.^{6,7} Patients at highest risk for this are those with longstanding poor control with some degree of preexisting retinopathy.⁸ Absence of any retinopathy at the initiation of improved control does not result in any acute problems.

Patients at high risk of early worsening should have more frequent ophthalmologic evaluations. Although not yet formally studied, a common recom-

mendation is a slower improvement in glycemic control for these patients.

The mechanism for this condition is possibly an acute reduction in retinal blood flow, which results in retinal hypoxia and subsequent “cotton wool” exudates (micro-infarcts), capillary dropout, and neovascularization. This also may be related to an upregulation of intraocular insulin-like growth factor-1 (IGF-1) levels.⁹

Finally, anemia appears to be an independent risk factor for diabetic retinopathy.^{10,11} Furthermore, an acute reduction in hematocrit may result in exacerbation of retinopathy.¹² Although not as well documented as the changes in glycemia, retinal hypoxia is probably the most important mechanism. Over the years we have seen several episodes of an acute anemia resulting in an acute worsening of retinopathy. For this reason, it seems prudent to be aggressive in replacing iron or even blood for an acute blood loss (e.g., because of surgery or gastrointestinal bleeding).

Although more research is needed, health care providers who are not eye specialists need to be more knowledgeable about and involved in the treatment of diabetic retinopathy. In addition to blood glucose control and appropriate screening as noted in the position statement, current studies suggest the importance of aggressive blood pressure control with an ACE inhibitor, slow improvement of glycemic control if preexisting retinopathy is present (the appropriate rate of decrease in HbA_{1c} is not yet known), and aggressive treatment of acute anemia.

REFERENCES

¹Aiello LP, Gardner TW, King GI, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Diabetic retinopathy (Technical Review). *Diabetes Care* 21:143–156, 1998

²United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications of type 2 diabetes (UKPDS 38). *BMJ* 317:703–713, 1998

³Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keippes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLOD Study Group. *Lancet* 351:28–31, 1998

⁴Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet* 355:253–259, 2000

⁵Williams B: Antiotensin II, VEGF, and diabetic retinopathy. *Lancet* 351:837–838, 1998

⁶The DCCT Research Group: Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Arch Ophthalmol* 116:874–886, 1998

⁷Henricsson M, Nilsson A, Janzon L, Groop L: The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. *Diabetic Med* 14:123–131, 1997.

⁸Moskalets E, Galstyan G, Starostina E, Antsiferov M, Chantelau E: Association of blindness of intensification of glycemic control in insulin-dependent diabetes mellitus. *J Diabetes Complications* 8:45–50, 1994

⁹Chantelau E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. *Br J Ophthalmol* 82:725–730, 1998.

¹⁰Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL, Knatterud GL: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. *Invest Ophthalmol Vis Sci* 29:233–252, 1998

¹¹Qiao Q, Keinanen-Kiukaanniemi S, Laara E: The relationship between hemoglobin levels and diabetic retinopathy. *J Clin Epidemiol* 50:153–158, 1997

¹²Melberg NS, Grand MG, Rup D: The impact of acute lymphocytic leukemia on diabetic retinopathy. *J Pediatr Hematol Oncol* 17:81–84, 1995.

Irl B. Hirsch, MD, is an associate professor of medicine and medical director of the Diabetes Care Center at the University of Washington School of Medicine in Seattle. He is editor-in-chief of Clinical Diabetes.